Healthcare Industry News: BD
News Release - June 20, 2017
BD Receives FDA 510(k) Clearance for New Line of Customizable, 3.0mm Micro-Laparoscopic InstrumentsNew Micro-Laparoscopic Instruments Offer Surgeons Less Invasive Option for Patients
FRANKLIN LAKES, N.J., June 20, 2017 -- (Healthcare Sales & Marketing Network) -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its new line of Snowden-Pencer™ 3.0mm laparoscopic ergonomic take-apart instruments received U.S. Food and Drug Administration (FDA) 510(k) clearance for use in laparoscopic surgery.
The new line of Snowden-Pencer 3.0mm laparoscopic ergonomic take-apart instruments are designed for micro-laparoscopic surgery and function like 5.0mm instruments. The jaw lengths of the devices mirror those of standard laparoscopic instruments, providing surgeons with a less invasive approach without compromising instrument functionality.
The launch of this new line enables BD to offer one of the most customizable portfolios of 3.0mm micro-laparoscopic instruments available. It offers 26 different jaw patterns, 2 different lengths (24cm, 36cm) and 6-take-apart handles, resulting in 312 combinations to target procedures in multiple specialties. The micro-laparoscopic devices are also compatible with an interchangeable modular system that includes the standard Snowden-Pencer 5.0mm and 10.0mm laparoscopic instruments.
The new Snowden-Pencer micro-laparoscopic instrument is used in procedures known to provide patients with a virtually scar-less procedure, reduce post-operative pain, improve post-operative appearance and reduce hospital stays.1
"Minimally invasive micro-laparoscopic surgery is a steadily growing field resulting from patient demand for less invasive surgical options and scar reduction," said Jim Leitl, worldwide vice president and general manager of Infection Prevention, V. Mueller and Interventional Specialties for BD. "This innovative new line of instruments enables providers to choose the best surgical option for their patients."
The new line of micro-laparoscopic devices is the latest in BD's line of take-apart surgical instruments that are designed for easy assembly and disassembly to support sterility initiatives and are engineered to withstand demanding sterile processing techniques. For more information visit: http://www.carefusion.com/our-products/surgical-instruments/
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has nearly 50,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit bd.com.
1. Redan JA, Humphries AR, Farmer B, et al. Big operations using mini instruments: the evolution of mini laparoscopy in the surgical realm. Surg Technol Int. 2015;27:19–30.
Source: Becton, Dickinson
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBD Launches First and Only Fully Sterile Povidone-Iodine and Isopropyl Alcohol Skin Preparation
BD Launches Portable, Rapid Point-of-Care Antigen Test to Detect SARS-CoV-2 in 15 minutes, Dramatically Expanding Access to COVID-19 Testing
BD, BioGX Announce FDA Emergency Use Authorization for New COVID-19 Diagnostic for Use in U.S.